Overcoming sparseness of biomedical networks to identify drug repositioning candidates
نویسندگان
چکیده
منابع مشابه
Overcoming Obstacles to Drug Repositioning in Japan
Drug repositioning (DR) is the process of identifying new indications for existing drugs. DR usually focuses on drugs that have cleared phase-I safety trials but has yet to show efficacy for the intended indication. Therefore, DR can probably skip the preclinical and phase-I study, which can reduce the cost throughout drug development. However, the expensive phase-II/III trials are required to ...
متن کاملCollocation Map for Overcoming Data Sparseness
Statistical language models are useful because they can provide probabilistic information upon uncertain decision making. The most common statistic is n-grams measuring word cooccurrences in texts. The method suffers from data shortage problem, however. In this paper, we suggest Bayesian networks be used in approximating the statistics of insufficient occurrences and of those that do not occur ...
متن کاملPolymethyoxy Flavonoids: Possible Candidates for Overcoming Drug Resistance
The success of chemotherapy in cancer treatment is frequently limited by intrinsic or acquired multidrug resistance due to increased expression of a plasma membrane P-glycoprotein [1]. P-glycoprotein is an ATP-dependent transporter that effluxes many lipophilic anticancer agents out of cells, thereby reducing intracellular drug concentration and results in cancer cell survival. It has been repo...
متن کاملIdentify drug repurposing candidates by mining the Protein Data Bank
Predicting off-targets by computational methods is gaining increasing interest in early-stage drug discovery. Here, we present a computational method based on full 3D comparisons of 3D structures. When a similar binding site is detected in the Protein Data Bank (PDB) (or any protein structure database), it is possible that the corresponding ligand also binds to that similar site. On one hand, t...
متن کاملDrug Repositioning in Cancer
The development of new therapeutic agents, in any kind of disease, requires either long time or high costs; indeed 10 15 years of research are required to market a drug, resulting in an overall cost of about 1.8 billion dollars [1]. In addition, drug development in oncology is very challenging due to cancer biological complexity, actually comprising several subtypes of diseases carrying differe...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: IEEE/ACM Transactions on Computational Biology and Bioinformatics
سال: 2021
ISSN: 1545-5963,1557-9964,2374-0043
DOI: 10.1109/tcbb.2021.3059807